<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter/Institution</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-14:30</td>
<td>Poster Session II &amp; Lunch</td>
<td></td>
<td>(Foyer and Seminar Rooms First Floor)</td>
</tr>
<tr>
<td>14:00-16:30</td>
<td>Session 7 – Target discovery in cancer</td>
<td>Svenja Wiechmann, Goethe University Frankfurt, DE</td>
<td>Targeting Ras interactions: engineered Ras-binding domains as potent competitive inhibitors of oncogenic Ras</td>
</tr>
<tr>
<td>14:00-16:30</td>
<td>Session 7 – Target discovery in cancer</td>
<td>Manuel Kaulich, Goethe University Frankfurt, DE</td>
<td>High-fidelity multiplexed CRISPR/Cas libraries for functional interrogations</td>
</tr>
<tr>
<td>14:30-16:30</td>
<td>Session 7 – Target discovery in cancer</td>
<td>Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, US</td>
<td>Identification of new cancer vulnerabilities with functional genomic screens</td>
</tr>
<tr>
<td>14:30-16:30</td>
<td>Session 7 – Target discovery in cancer</td>
<td>Ivan Dikic, Goethe University Frankfurt, DE</td>
<td>Ubiquitin networks in cancer pathogenesis</td>
</tr>
<tr>
<td>14:30-16:30</td>
<td>Session 7 – Target discovery in cancer</td>
<td>Joseph Schlessinger, Yale University School of Medicine, New Haven, US</td>
<td>The role of endocrine FGFs in metabolism and cancer</td>
</tr>
<tr>
<td>16:30-17:00</td>
<td>Coffee Break (Foyer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00-19:00</td>
<td>Session 8 – Targeting the untargetable: Myc and epigenetic reader domains</td>
<td>Martin Eilers, University Würzburg, DE</td>
<td>MYCN in neuroblastoma: coordinating transcription and DNA replication</td>
</tr>
<tr>
<td>17:00-19:00</td>
<td>Session 8 – Targeting the untargetable: Myc and epigenetic reader domains</td>
<td>Laura Soucek, Vall d’Hebron Institute of Oncology, Barcelona, ES</td>
<td>Inhibiting Myc with Oromyc-derived peptides</td>
</tr>
<tr>
<td>18:00-18:25</td>
<td>Stefan Knapp, Goethe University Frankfurt, DE</td>
<td>Stefan Knapp, Goethe University Frankfurt, DE</td>
<td>Targeting epigenetic reader domains in cancer</td>
</tr>
<tr>
<td>18:30-18:55</td>
<td>Simone Fulda, Goethe University Frankfurt, DE</td>
<td>Simone Fulda, Goethe University Frankfurt, DE</td>
<td>Novel opportunities for therapeutic targeting of cell death pathways</td>
</tr>
<tr>
<td>19:00</td>
<td>Conference Dinner (Foyer and Terrace First Floor)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Wednesday, 26 September 2018

08:30-09:00 Registration (Foyer)

09:00-10:45 Session 1 – From cancer stem cells to tumor heterogeneity and treatment resistance
  Session Chairs: Daniela Krause, Richard Marais
  09:00-09:25 Sean Morrison, University of Texas Southwestern, Dallas, US: The metabolic regulation of cancer progression
  09:30-09:55 Priscilla K. Brastianos, Harvard Medical School, Boston, US: Genomic evolution of brain metastases
  10:00-10:25 Andreas Trump, German Cancer Research Center, Heidelberg, DE: Stem cell features in cancer and therapy resistance
  10:30-10:40 Anna Lorentzen, Aarhus University, Aarhus, DK: Liquid-phase single-cell polarity facilitates tumor cell attachment, adhesion and metastasis

10:45-11:15 Coffee Break (Foyer)

11:15-12:45 Session 2 – Novel approaches for improved precision oncology
  Session Chairs: René Bernards, Simone Fulda
  11:15-11:40 Jürgen Ruland, Technical University Munich, DE: Antigen receptor and co-receptor signaling pathways in lymphoma: the dark side
  12:00-12:10 Kivanc Görgülü, Technical University Munich, DE: Levels of Autophagy-related gene (Atg5) determine pancreatic tumor formation and metastasis in mice
  12:15-12:40 Lars Zender, University Hospital Tübingen, DE: Translating cancer biology: from functional target discovery to academic drug discovery and development
  12:45-12:55 Simon Kreutzfeldt, National Center for Tumor Diseases, Heidelberg, DE: Integration of comprehensive molecular profiling into clinical practice

13:00-14:00 Lunch Break (Mensa)

14:00-16:15 Session 3 – From oncogenic signaling to targeting pathways
  Session Chairs: Laura Soucek, Peter Wild
  14:00-14:10 Markus Morkel, Charité – Universitätsmedizin, Berlin, DE: Cell type-dependent differential activation of ERK by oncogenic KRAS or BRAF in the mouse intestinal epithelium
  14:15-14:40 Stefan Pfister, National Center for Tumor Diseases Heidelberg, DE: Novel molecular targets in childhood brain tumors
  14:45-15:10 Richard Marais, Cancer Research UK Manchester Institute, UK: Lysyl oxidase regulates tumor cellularity
  15:15-15:40 Thomas Oellerich, Goethe University Frankfurt, DE: Therapeutic strategies revealed by proteogenomics
  15:45-16:10 Bernhard Küster, Technical University Munich, DE: The target landscape of clinical kinase drugs

16:15-16:45 Coffee Break (Foyer)

16:45-18:30 Session 4 – Cancer metabolism: from understanding to intervention
  Session Chairs: Rolf Marschall, Joachim Steinbach
  16:45-17:10 Simone Niclou, Luxembourg Institute of Health, LU: Harnessing metabolic specificities of IDH mutant glioma for novel therapies
  17:15-17:25 Dietrich A. Ruess, Technical University Munich, DE: Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
  17:30-17:55 Matthew Vander Heiden, Massachusetts Institute of Technology, Cambridge, US: Considerations to target metabolism for cancer therapy

18:30-20:00 Poster Session I

Thursday, 27 September 2018

08:30-09:00 Registration (Foyer)

09:00-10:45 Session 5 – Tumor microenvironment and metastasis
  Session Chairs: Claus Rödel, Kimberly Stegmaier
  09:00-09:25 Michael Karin, University of California San Diego, US: Metabolic and immune control of liver tumorigenesis
  09:30-09:55 Florian Greten, Georg-Speyer-Haus, Frankfurt, DE: Modeling colorectal cancer progression

10:00-10:25 Raghu Kalluri, University of Texas, Houston, US: Functional contribution of tumor microenvironment and exosomes in the biology and treatment of pancreatic cancer

10:30-10:40 Ramona Schulz-Heddergott, University Medical Center Göttingen, DE: Therapeutic ablation of stabilized gain-of-function mutant p53 in colorectal cancer inhibits Stat3-mediated tumor growth and invasion

10:45-11:15 Coffee Break (Foyer)

11:15-12:45 Session 6 – Immunotherapy beyond checkpoint-inhibition
  Session Chairs: Bernhard Brüne, Tak W. Mak
  11:15-11:40 Michael Platten, University Heidelberg, DE: Challenges in brain tumor immunotherapy
  11:45-11:55 Fabian Coscia, University of Copenhagen, DK: Multi-level proteomics identifies a novel mediator of chemosensitivity and immunotherapy target in ovarian cancer
  12:00-12:10 Emmanuel Fokas, Goethe University Frankfurt, DE: The stromal immune contexture of pancreatic ductal adenocarcinoma and rationale for combination of radiotherapy with immunotherapy
  12:15-12:25 Frederic B. Thalheimer, Paul-Ehrlich-Institute, Langen, DE: In vivo generation of human CD19-CAR T cells results in B cell depletion and signs of cytokine release syndrome

12:30-12:55 Poster Session II

B Finger Food (Foyer and Seminar Rooms First Floor)